From the web site.
"AVAX is developing a proprietary Autologous Cell (AC) Vaccine® Platform, a therapy that stimulates a patient’s immune system to combat his/her own (autologous) tumor-specific cancer cells,
containing the most relevant antigens by use of whole tumor. AVAX’s MVax®, with an orphan drug designation, is positioned, pending financing, to enter a Phase III pivotal registration clinical trial for Stage IV melanoma approved by the FDA. The Company has also completed a Phase I/II clinical trial for ovarian cancer, using its OVax® vaccine at Cancer Treatment Centers of America (“CTCA”). Results from this trial have demonstrated survival rates and a sustained reduction of CA-125 levels that far surpass expectations for patients of this disease stage. Due to the dearth of Ovarian Cancer treatments and potentially additional evidence supporting ,the MVAX trial findings, AVAX believes results from a new, well-designed Phase IIb study in Ovarian could be a major value driver for the company. AVAX has been “dark” since 2008 due to financing concerns, but is seeking to re-list on a major exchange, under a reconstituted management team upon or contemporaneous with obtaining additional financing."
Notice the PHASE III M-Vax trial has been approved already by the FDA. Sounds like they just need the financing.
Hope they put out a BIG, FAT, PR when they get it!
